


Supplementary information

Advances in incretin-based drug discovery in 2025

In the format provided by
the authors and unedited



Supplementary Figure 1. Structural schematic and here discussed clinical outcome of Tirzepatide vs. Semaglutide (A)¹, Semaglutide 7.2 mg vs. 2.4 mg (B)², CagriSema vs. Semaglutide (C)³, MariTide (D)⁴ and Orforglipron (E)⁵. Letters in (D) correspond to: ^aOnce-monthly without dose-escalation, ^bOnce every other month without dose-escalation, ^cOnce-monthly with 4 week dose-escalation; ^dOnce-monthly with 12 week dose-escalation. The structure of semaglutide in Panel 1B is adapted from Müller et al., *Pharmacol. Rev.* 2018⁶, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>). The images of an antibody in Panel 1D, and a pill in Panel E are reprinted from smart.servier.com, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>).

References:

- 1 Aronne, L. J. et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. *N Engl J Med* **393**, 26-36, doi:10.1056/NEJMoa2416394 (2025);
- 2 Wharton, S. et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. *Lancet Diabetes Endocrinol*, doi:10.1016/S2213-8587(25)00226-8 (2025);
- 3 Garvey, W. T. et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. *N Engl J Med* **393**, 635-647, doi:10.1056/NEJMoa2502081 (2025);
- 4 Jastreboff, A. M. et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. *N Engl J Med* **393**, 843-857, doi:10.1056/NEJMoa2504214 (2025);
- 5 Wharton, S. et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. *N Engl J Med*, doi:10.1056/NEJMoa2511774 (2025);
- 6 Muller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D. & Tschop, M. H. Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. *Pharmacol Rev* **70**, 712-746, doi:10.1124/pr.117.014803 (2018).